Michael G McCully

president & CEO Gate Neurosciences - focused on tackling the challenges of developing new treatments in the area of CNS and neuropsychiatry

[Michael G McCully @Mike_McCully]

Excited to share that @GateNeuro acquired Boost Neurosciences, backed by Catalio Capital Management and based on Dr. Tom Sudhof's work, Nobel Laureate and Stanford Professor.

https://t.co/bYp6r0hbMA

[Ivan Zhao @ivanhzhao]

https://t.co/fxHYR6S29D

[Eric Topol @EricTopol]

We need a lot more Dr. Jessica Steiers to pull a body of evidence together like this
@unbiasedscipod
https://t.co/LjskEPP5qM
https://t.co/g90BHZ0onM

[American Society of Clinical Pschopharm (ASCP) @ASCPorg]

Dr. Anantha Shekhar spoke about the development of GATE-251, a positive allosteric modulator of the NMDA receptor to treat MDD in subjects with insomnia and anxiety in a Phase 2a study that demonstrated rapid efficacy which warrants further investigation.

[Michael G McCully @Mike_McCully]

@EllenYChang https://t.co/EsRWibthEy

[Michael G McCully @Mike_McCully]

There are baggage delivery services at the airport (Yamato is a major one) that will deliver your luggage. Just drop the bag and tell them when/where and they deliver. It’s an amazing thing that I’ve only see in Japan. Hotels in Japan will transfer your luggage so you don’t have to take it on the train.

[Michael G McCully @Mike_McCully]

New white paper out today! From our team at @GateNeuro describing our insights into harnessing the potential of new treatments targeting synaptic structure and function. https://t.co/mSEhXFr31U

[Michael G McCully @Mike_McCully]

@michael_gilman Manhattan or similar dark cocktail with a maraschino representation of the moon 🌑

[Drug Discovery & Development @DrugDiscoverDev]

In this article, Gate Neurosciences details their role on taking on depression with event-driven #pharmacology.

They also discuss he challenges & promise of NMDA receptor #modulation, the role of EEG #biomarkers in #DrugDevelopment & much more: https://t.co/6DE0twGWHU

[Gate Neurosciences @GateNeuro]

Great to see coverage in @WIRED on the link between #neuroplasticity and #depression.

Current antidepressants take weeks to work. We are developing a new class of drugs targeting the #glutamate system to rapidly enhance neuroplasticity within hours to days.

#mentalhealth

[Gate Neurosciences @GateNeuro]

Nice @TheAtlantic piece on how psychedelics hallucinogenic effects may not drive #mentalhealth outcomes - its the impact on neuroplasticity. Our novel drug candidates can safely enhance plasticity & strengthen neural connections to treat disease from #MDD to #alzheimers & #autism

[Gate Neurosciences @GateNeuro]

Our lead program, zelquistinel, was included in a recent review paper from @UTHealthHouston on GABA-glutamate targeted drugs:
https://t.co/MpBMh5C8kq

"Future treatment models need to consider nuances of glutamate signaling with regard to timing & duration of action"...we agree!

[Michael G McCully @Mike_McCully]

Looking forward to presenting at CNS Summit next week in Boston!

#cnssummit2023 #neuroscience #mentalhealth #neuroplasticity #drugdevelopment #biopharma #innovation #pharma https://t.co/YYFiQYPtb4

[American Psychiatric Association @APApsychiatric]

🌍 Today we celebrate mental health around the world—because every mind matters. 💚 Let's foster understanding, empathy, and support for one another. 🤝 #WorldMentalHealthDay #MentalHealthMatters 🌍

[Michael G McCully @Mike_McCully]

#WorldMentalHealthDay

[WorldMentalHealthDay @WMHDay]

TODAY IS WORLD MENTAL HEALTH DAY! Let's make #WorldMentalHealthDay top trending. Attention on social media can lead to more awareness and give #mentalhealth a higher priority worldwide. Please help us to reach as many people as possible by retweeting and using our hashtag💚

[Michael G McCully @Mike_McCully]

Amazing 🤯

[CNBC's Fast Money @CNBCFastMoney]

The one and only @OzTheMentalist is blowing Wall Street minds!

See the magic with @timseymour, @guyadami, @karenfinerman and @melissaleeCNBC